Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Summary

The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.

Timeline

Start

2020-01-21

Primary completion

2022-10-11

Completion

2022-10-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor R\&D Strategy Adjustment”

Drugs

Indications